Resistance to anti-Epidermal Growth Factor Receptor in metastatic colorectal cancer: what does still need to be addressed?

Survival rate for metastatic colorectal cancer (mCRC) at five years remains poor[1]. Approved standard chemotherapy and targeted treatments have provided increased survival outcomes in the last years but still a too small number of patients could really experience a long-term benefit. This is due to the presence of mechanisms of resistance that occur before or during the treatment and impact negatively on drug efficacy. Many efforts have been made to enlarge the understanding of the complex panorama of CRC heterogeneity and offer the best tailored treatment to any single patient.

Source: Cancer Treatment Reviews - April 12, 2020 Category: Cancer & Oncology Authors: Giulia Martini, Davide Ciardiello, Pietro Paolo Vitiello, Stefania Napolitano, Claudia Cardone, Antonio Cuomo, Teresa Troiani, Fortunato Ciardiello, Erika Martinelli Tags: New Drugs Source Type: research